PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra.
Consultant Pulmonologist, Advanced Multi Specialty Hospitals, Mumbai, Maharashtra.
J Assoc Physicians India. 2021 Sep;69(9):11-12.
India has a disproportionately high burden of acute and chronic pulmonary diseases. In India, 65 million suffer from non-communicable respiratory diseases. The outbreak of the novel coronavirus disease 2019 (COVID-19) had worsened the situation. Patients affected with COVID-19 with a previous history of comorbidities, such as COPD and chronic lung diseases, had the worst prognosis, resulting in adverse outcomes, such as acute respiratory distress syndrome (ARDS) and pneumonia. Immune modulation strategies have since gained a lot of traction amongst practitioners. Modulation of the immune system with Pidotimod along with standard-of-care (SOC) treatment has proven efficacious in the past two decades in patients with recurrent respiratory tract infections (RRTIs), bronchitis, COPD, and pneumonia. In this article, we have reviewed the current unmet needs in the management of COPD in India and evaluated the usage of Pidotimod in adult COPD patients based on expert panel discussion.
印度患有急性和慢性肺部疾病的人数不成比例地高。在印度，有 6500 万人患有非传染性呼吸系统疾病。新型冠状病毒病 2019（COVID-19）的爆发使情况恶化。患有 COVID-19 且有合并症既往史的患者，如 COPD 和慢性肺部疾病，预后最差，导致不良后果，如急性呼吸窘迫综合征（ARDS）和肺炎。免疫调节策略自此在从业者中得到了广泛关注。过去二十年，在复发性呼吸道感染（RRTIs）、支气管炎、COPD 和肺炎患者中，使用比度提莫德联合标准治疗（SOC）对免疫系统进行调节已被证明是有效的。在本文中，我们回顾了印度 COPD 管理中的未满足需求，并根据专家小组讨论评估了比度提莫德在成年 COPD 患者中的使用。
